Welcome to our dedicated page for Amyris news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, Inc. (Nasdaq: AMRS) will host its third webinar in a virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology" on April 22, 2021, at 1:00 pm ET. This session will cover the roadmap for Amyris's ingredients portfolio and include a Q&A session. Key topics include valuation of molecules, long-term partner collaborations, and insights into recent strategic transactions. The webinar will feature the CEO of Minerva Foods. Interested participants can join via a live audio webcast or call.
Amyris, Inc. (Nasdaq: AMRS) has closed a significant agreement with DSM Nutritional Products Ltd. for exclusive rights to supply its flavor and fragrance ingredients, valued at over $500 million. This amount includes an upfront payment, earn-out payments over three years, and a 15-year manufacturing agreement. The collaboration aims to enhance the development of clean, sustainable chemistry in the industry. Amyris expects this transaction and its first-quarter performance to contribute nearly half of its total anticipated revenue for 2021.
Amyris, Inc. (Nasdaq: AMRS) announced a significant achievement in producing Cannabigerol (CBG) from fermentation for skincare applications. This production run marks the largest industrial-scale fermentation-based CBG production to date, utilizing 225,000 fermenters at its Spain facility. Amyris anticipates selling one million retail units of CBG over the next year. The CBG molecule outperforms CBD in clinical studies for skin care applications. CEO John Melo highlighted their market leadership in sustainable ingredients and upcoming strategic transactions expected to enhance company performance.
Amyris, Inc. (Nasdaq: AMRS) announced a partnership with Minerva Foods to develop sustainable animal protein molecules. Funded by Minerva, Amyris will create new molecules, including natural preservatives that enhance meat shelf-life while reducing CO2 emissions. The commercialization of the first product is expected within 18 months. This collaboration is anticipated to generate several million dollars in revenue this year and contributes to Amyris's long-term growth. Definitive agreements are expected to be signed in the coming weeks, with closure anticipated in Q2 2021.
Amyris, Inc. (Nasdaq: AMRS) announced a partnership with Minerva Foods to develop sustainable molecules for animal protein production. Funded by Minerva, Amyris aims to create solutions for meat preservation that enhance shelf-life and reduce CO2 emissions. The first commercialization is anticipated within 18 months. This partnership is expected to generate several million dollars in revenue for Amyris this year, furthering its growth into the fermentation-based protein market. Definitive agreements are to be finalized by Q2 2021.
Amyris, a leader in sustainable biotechnology, will participate in a fireside chat at the 33rd Annual Roth Conference on March 17, 2021, at 1:00 pm ET. This event will be hosted virtually, with a live webcast available on the company's Investor Relations website. Amyris specializes in developing clean and natural ingredients for health and beauty markets through a proprietary synthetic biology platform, impacting over 200 million consumers globally.
Amyris, Inc. (Nasdaq: AMRS) reported strong financial results for Q4 and the full year of 2020. Q4 sales revenue reached $80 million, nearly doubling year-over-year, with a significant 71% growth in Product revenue. The Consumer segment saw a remarkable 161% increase, equating to the entire revenue of 2019 in just Q4. The company completed a $200 million equity financing and reduced debt to $171 million. For 2021, Amyris expects underlying total revenue of about $240 million, with reported revenue around $400 million, projecting continued positive adjusted EBITDA.
Amyris, Inc. (Nasdaq: AMRS) announced on March 1, 2021, its agreement to acquire Costa Brazil, a clean luxury beauty brand co-founded by Francisco Costa. This acquisition aims to enhance Amyris's position in the clean beauty sector, expanding its portfolio alongside brands like Biossance and Pipette. Costa Brazil’s products, driven by sustainable ingredients from the Amazon, align with Amyris’s commitment to social responsibility and clean formulation. Francisco Costa will join as Chief Creative Officer, expected to bring his expertise to further the company's growth in this booming market.
Amyris, Inc. (Nasdaq: AMRS) announced its participation in two upcoming investor conferences. These events include the Cowen 41st Annual Health Care Conference on March 4 at 12:10 PM ET and the H.C. Wainwright Global Life Sciences Conference on March 9 at 1:30 PM ET. Webcasts of the presentations will be available on the company's Investor Relations website. Amyris is known for its sustainable ingredients in the Clean Health and Beauty markets, reaching over 200 million consumers through its popular brands.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
